Polish commercial clinical trials market an opportunity for patients and national economy

7 March 2022

Over 25,000 patients participated in commercial clinical trials conducted in Poland in 2020, gaining access to innovative therapies, according to a posting on the website of the leading pharma trade group, INFARMA.

Over the last 10 years, the country has significantly advanced by taking the 11th position in the world ranking of the largest commercial clinical trials markets. However, in the absence of decisive, far-reaching measures supporting the attractiveness of the country for sponsors of clinical trials, a decline in the value of this market in Poland within the next 10 years is practically inevitable.

Therefore, in order to strengthen Poland's position in the international arena and provide as many Polish patients as possible access to innovative therapies as part of clinical trials, it is necessary to continue cooperation to strengthen the potential of research and to follow the example of world leaders in this sector of the economy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK